Hutchison China Meditech Limited Annual Financial Report (3492H)
25 Mars 2020 - 8:00AM
UK Regulatory
TIDMHCM
RNS Number : 3492H
Hutchison China Meditech Limited
25 March 2020
2019 Annual Report and
Notice of Annual General Meeting
London: Wednesday, March 25, 2020: Hutchison China MediTech
Limited ("Chi-Med") (Nasdaq/ AIM: HCM) today announces that its
2019 Annual Report together with the Notice of Annual General
Meeting and the Form of Proxy ("AGM Materials") have been posted to
Shareholders of Chi-Med ("Shareholders"). The documents can be
accessed from the website of Chi-Med ( www.chi-med.com ).
Due to travel restrictions resulting from the novel coronavirus
outbreak, the 2020 Annual General Meeting ("AGM") will be held at
the 47th Floor, C heung Kong Center, 2 Queen's Road Central, Hong
Kong on Monday, April 27, 2020 at 6:00 pm Hong Kong Time (11:00 am
London Time).
To safeguard the health and safety of Shareholders, Chi-Med
encourages Shareholders to exercise their right to vote at the AGM
by appointing the Chairman of the AGM as their proxy instead of
attending the AGM in person. Shareholders will be able to view a
live webcast of the AGM through the website of the Company at
https://www.chi-med.com/agm2020/ . Along with the AGM Materials,
all registered Shareholders will also receive a letter containing
log in details and information on how to access the webcast. Please
note that webcast participation does not constitute formal
attendance at the AGM nor would Shareholders be able to vote
electronically. Shareholders would need to submit their form of
proxy ahead of the AGM in accordance with the instructions printed
thereon if they wish to cast their votes.
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical
company committed, over the past twenty years, to the discovery and
global development of targeted therapies and immunotherapies for
the treatment of cancer and immunological diseases. It has a
portfolio of eight cancer drug candidates currently in clinical
studies around the world and extensive commercial infrastructure in
its home market of China. For more information, please visit:
www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Asia - Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile)
jlo@brunswickgroup.com
- Zhou Yi, Brunswick +852 97 83 6894 (Mobile)
y zhou@brunswickgroup.com
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACSSEASALESSEID
(END) Dow Jones Newswires
March 25, 2020 03:00 ET (07:00 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024